Acute Leukemias

SAN DIEGO — Researchers reported encouraging early results from novel therapies targeting menin in patients with relapsed or refractory acute leukemias harboring specific genetic alterations.

Revumenib conferred complete remission or complete remission with partial hematologic recovery in nearly one-quarter of patients with two acute leukemia subtypes, according to the agent’s manufacturer.